Enhanced targeting with heterobivalent ligands

Molecular Cancer Therapeutics

Volumn 8, Issue 8, 2009, Pages 2356-2365

  Xu, Liping ^a   Vagner, Josef ^b   Josan, Jatinder ^b   Lynch, Ronald M ^c   Morse, David L ^a   Baggett, Brenda ^a   Han, Haiyong ^d   Mash, Eugene A ^b   Hruby, Victor J ^a,b   Gillies, Robert J ^a,c,e  

^a UNIVERSITY OF ARIZONA   (United States)

^b The University of Arizona   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^e H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERMEDIN; ANTINEOPLASTIC AGENT; CHOLECYSTOKININ B RECEPTOR; CHOLECYSTOKININ HEXAPEPTIDE; CHOLECYSTOKININ OCTAPEPTIDE; DELTA OPIATE RECEPTOR; DELTORPHIN; DELTORPHIN II; EUROPIUM; EUROPIUM (PENTETIC ACID)ASPARTYLTYROSYLNORLEUCYLGLYCYLTRYPTOPHYLNORLEUCYLASPARTYLPHENYLALANINAMIDE; EUROPIUM (PENTETIC ACID)SERYLTYROSYLSERYLNORLEUCYLGLUTAMYLHISTIDYL DEXTRO PHENYLALANYLARGINYLTRYPTOPHYLGLYCYLPROLYLVALINAMIDE; G PROTEIN COUPLED RECEPTOR; HETEROBIVALENT LIGAND; INTERMEDIN; INTERMEDIN DERIVATIVE; LIGAND; MELANOCORTIN 4 RECEPTOR; SERYLNORLEUCYLGLUTAMYLHISTIDYL DEXTRO PHENYLALANYLARGINYLTRYPTOPHAN; TYROSINE CYCLO(DEXTRO PHENYLALANYLGLYCYLPHENYLALANYLCYSTEINYL)PHENYLALANYLLYSINE [EUROPIUM (PENTETIC ACID)] AMINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL STRAIN HEK293; CHO CELL; CONTROLLED STUDY; CROSS LINKING; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG SYNTHESIS; DRUG TARGETING; FLUORESCENCE; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL;

ALPHA-MSH; ANIMALS; ANTINEOPLASTIC AGENTS; BINDING, COMPETITIVE; CELLS, CULTURED; CHO CELLS; CRICETINAE; CRICETULUS; HUMANS; LIGANDS; ORGANOMETALLIC COMPOUNDS; PENTETIC ACID; PEPTIDES; RECEPTOR, CHOLECYSTOKININ B; RECEPTOR, MELANOCORTIN, TYPE 4; RECEPTORS, OPIOID, DELTA; TRANSFECTION;

EID: 68849122747     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-1183     Document Type: Article

References (44)

1. Finley RS. Overview of targeted therapies for cancer. Am J Health Syst Pharm 2003;60:S4-10.
2. Lindsay MA. Target discovery. Nat Rev Drug Discov 2003;2:831-8.
3. Ross JS, Schenkein DP, Pietrusko R, et al. Targeted therapies for cancer 2004. Am J Clin Pathol 2004;122:598-609.
4. Kaptain S, Tan LK, Chen B. Her-2/neu and breast cancer. Diagn Mol Pathol 2001;10:139-52.
5. Gillies RJ, Hruby VJ. Expression-driven reverse engineering of targeted imaging and therapeutic agents. Expert Opin Ther Targets 2003;7:137-9.
6. Handl HL, Vagner J, Han H, Mash E, Hruby VJ, Gillies RJ. Hitting multiple targets with multimeric ligands. Expert Opin Ther Targets 2004;8:565-86.
7. Shadidi M, Sioud M. Selective targeting of cancer cells using synthetic peptides. Drug Resist Updat 2003;6:363-71.
8. Kiessling LL, Gestwicki JE, Strong LE. Synthetic multivalent ligands in the exploration of cell-surface interactions. Curr Opin Chem Biol 2000;4:696-703.
9. Mammen M, Choi S-K, Whitesides GM. Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors. Angew Chem Int Ed 1998;37:2754-94.
10. Dam TK, Roy R, Das SK, Oscarson S, Brewer CF. Bindingof multivalent carbohydrates to concanavalin A and Dioclea grandiflora lectin. Thermodynamic analysis of the "multivalency effect". J Biol Chem 2000;275:14223-30.
11. Pluckthun A, Pack P. New protein engineering approaches to multivalent and bispecific antibody fragments. Immunotechnology 1997;3:83-105.
12. Todorovska A, Roovers RC, Dolezal O, Kortt AA, Hoogenboom HR, Hudson PJ. Design and application of diabodies, triabodies and tetrabodies for cancer targeting. J Immunol Methods 2001;248:47-66.
13. Vagner J, Handl HL, Gillies RJ, Hruby VJ. Novel targeting strategy based on multimeric ligands for drug delivery and molecular imaging: homooligomers of α-MSH. Bioorg Med Chem Lett 2004;14:211-5.
14. Schrama D, Reisfeld RA, Becker JC. Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 2006;5:147-59.
15. Segota E, Bukowski RM. The promise of targeted therapy: cancer drugs become more specific. Cleve Clin J Med 2004;71:551-60.
16. Shadidi M, Sioud M. Selection of peptides for specific delivery of oligonucleotides into cancer cells. Methods Mol Biol 2004;252:569-80.
17. Gestwicki JE, Cairo CW, Strong LE, Oetjen KA, Kiessling LL. Influencing receptor-ligand binding mechanisms with multivalent ligand architecture. J Am Chem Soc 2002;124:14922-33.
18. Sharma SD, Jiang J, Hadley ME, Bentley DL, Hruby VJ. Melanotropic peptide-conjugated beads for microscopic visualization and characterization of melanoma melanotropin receptors. Proc Natl Acad Sci U S A 1996;93:13715-20.
19. Shrivastava A, von Wronski MA, Sato AK, et al. A distinct strategy to generate high-affinity peptide binders to receptor tyrosine kinases. Protein Eng Des Sel 2005;18:417-24.
20. Handl HL, Vagner J, Yamamura HI, Hruby VJ, Gillies RJ. Lanthanide-based time-resolved fluorescence of in cyto ligand-receptor interactions. Anal Biochem 2004;330:242-50.
21. Handl HL, Vagner J, Yamamura HI, Hruby VJ, Gillies RJ. Development of a lanthanide-based assay for detection of receptor-ligand interactions at the δ-opioid receptor. Anal Biochem 2005;343:299-307.
22. Lynch RM, Fogarty KE, Fay FS. Modulation of hexokinase association with mitochondria analyzed with quantitative three-dimensional confocal microscopy. J Cell Biol 1991;112:385-95.
23. Lynch RM, Carrington W, Fogarty KE, Fay FS. Metabolic modulation of hexokinase association with mitochondria in livingsmooth muscle cells. Am J Physiol 1996;270:C488-99.
24. Chen R, Greene EL, Collinsworth G, et al. Enrichment of transiently transfected mesangial cells by cell sorting after cotransfection with GFP. Am J Physiol 1999;276:F777-85.
25. Davies A, Greene A, Lullau E, Abbott WM. Optimisation and evaluation of a high-throughput mammalian protein expression system. Protein Expr Purif 2005;42:111-21.
26. Ducrest AL, Amacker M, Lingner J, Nabholz M. Detection of promoter activity by flow cytometric analysis of GFP reporter expression. Nucleic Acids Res 2002;30:e65.
27. Xie Z, Bhushan RG, Daniels DJ, Portoghese PS. Interaction of bivalent ligand KDN21 with heterodimeric δ-κ opioid receptors in human embryonic kidney 293 cells. Mol Pharmacol 2005;68:1079-86.
28. Breit A, Lagace M, Bouvier M. Hetero-oligomerization between β2-and β3-adrenergic receptors generates a β-adrenergic signaling unit with distinct functional properties. J Biol Chem 2004;279:28756-65.
29. Wilson S, Wilkinson G, Milligan G. The CXCR1 and CXCR2 receptors form constitutive homo- and heterodimers selectively and with equal apparent affinities. J Biol Chem 2005;280:28663-74.
30. Sutton GM, Duos B, Patterson LM, Berthoud HR. Melanocortinergic modulation of cholecystokinin-induced suppression of feedingthroug h extracellular signal-regulated kinase signaling in rat solitary nucleus. Endocrinology 2005;146:3739-47.
31. Vaughan CH, Haskell-Luevano C, Andreasen A, Rowland NE. Effects of oral preload, CCK or bombesin administration on short term food intake of melanocortin 4-receptor knockout (MC4RKO) mice. Peptides 2006;27:3226-33.
32. Hirst RA, Smart D, Devi LA, Lambert DG. Effects of C-terminal truncation of the recombinant δ-opioid receptor on phospholipase C and adenylyl cyclase coupling. J Neurochem 1998;70:2273-8.
33. Chen L, Li G, Tang L, Wang J, Ge XR. The inhibition of lungcancer cell growth by intracellular immunization with LC-1 ScFv. Cell Res 2002;12:47-54.
34. Bonander N, Hedfalk K, Larsson C, et al. Design of improved membrane protein production experiments: quantitation of the host response. Protein Sci 2005;14:1729-40.
35. Grisshammer R. Understanding recombinant expression of membrane proteins. Curr Opin Biotechnol 2006;17:337-40.
36. Tate CG, Grisshammer R. Heterologous expression of G-protein-coupled receptors. Trends Biotechnol 1996;14:426-30.
37. Breitwieser GE. G protein-coupled receptor oligomerization: implications for G protein activation and cell signaling. Circ Res 2004;94:17-27.
38. Hur EM, Kim KT. G protein-coupled receptor signalling and cross-talk: achievingrapidity and specificity. Cell Signal 2002;14:397-405.
39. Maggio R, Novi F, Scarselli M, Corsini GU. The impact of G-protein-coupled receptor hetero-oligomerization on function and pharmacology. FEBS J 2005;272:2939-46.
40. Park PS, Filipek S, Wells JW, Palczewski K. Oligomerization of G protein-coupled receptors: past, present, and future. Biochemistry 2004;43:15643-56.
41. Vagner J, Xu L, Handl HL, et al. Heterobivalent ligands crosslink multiple cell-surface receptors: the human melanocortin-4 and δ-opioid receptors. Angew Chem Int Ed Engl 2008;47:1685-8.
42. Caplan MR, Rosca EV. Targeting drugs to combinations of receptors: a modelingan alysis of potential specificity. Ann Biomed Eng2005;33:1113-24.
43. Handl HL, Sankaranarayanan R, Josan JS, et al. Synthesis and evaluation of bivalent NDP-α-MSH(7) peptide ligands for binding to the human melanocortin receptor 4 (hMC4R). Bioconjug Chem 2007;18:1101-9.
44. Balagurunathan Y, Morse DL, Hostetter G, et al. Gene expression profiling-based identification of cell-surface targets for developing multimeric ligands in pancreatic cancer. Mol Cancer Ther 2008;7:3071-80.